比较传统与数字软件支持管理甲状腺功能减退症的成本效果分析
本研究采用决策分析马尔可夫状态转移模拟模型,模拟10000例40岁甲状腺功能减退症患者,比较可穿戴/移动端甲状腺功能数字监测方案与传统管理的成本效果。作者认为数字监测方案在甲状腺功能减退症管理中具有正向成本效果,其成本与灵敏度是关键影响因素。
要点
- 数字监测组每获得1个QALY的ICER为17988.97美元
- 在32255美元/QALY支付意愿阈值下,99%迭代中数字监测为最优策略
- ICER对数字监测方案的年成本最敏感
核心结论
- 与传统管理相比,引入数字监测方案在甲状腺功能减退症管理中显示出正向成本效果。
- 数字监测方案的成本及其灵敏度是决定成本效果的关键因素。
研究设计与样本
- 决策分析马尔可夫状态转移模拟模型,模拟10000例40岁甲状腺功能减退症患者,从卫生保健部门视角评估成本与健康结局。
- 采用4.5%年贴现率,成本调整至2022年水平,以增量成本效果比(ICER)呈现终身结局,并进行确定性和概率敏感性分析。
主要发现
- 数字监测支持组额外获得0.65个质量调整生命年(QALY),增量成本为11700.87美元,ICER为17988.97美元/QALY。
- 在32255美元/QALY的支付意愿阈值下,数字驱动软件在99%的迭代中为最优策略。
- ICER对甲状腺功能减退症数字监测方案的年成本最敏感。
关键数值与推荐
- 数字监测支持组较传统管理额外获得0.65个QALY,增量成本11700.87美元。
- ICER为17988.97美元/QALY。
- 在32255美元/QALY支付意愿阈值下,99%的迭代中数字监测为最优策略。
临床怎么用
- 作者认为,在真实世界临床实践中,需在数字监测支持的成本、激素水平监测的精确性及其对特定甲状腺功能减退症患者群体的有效性之间取得平衡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Wearable devices can now leverage the established correlation between thyroid function and heart rate to monitor thyroid function alongside exercise levels and heart rate. The objective was to assess the cost-effectiveness of introducing a wearable/mobile-based thyroid function digital monitoring solution for the management of hypothyroidism compared to the conventional management approach. METHODS: A decision-analytic Markov state-transition simulation model employed for using a simulated cohort of 10 000 40-year-old patients with hypothyroidism to estimate costs and health outcomes. Cost-effectiveness from the health care sector perspective was evaluated using a 4.5% annual discount rate and the costs adjusted to 2022 levels, and lifetime outcomes were presented through incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses evaluated the robustness of the results. RESULTS: The digital monitoring solution supported group yielded an additional 0.65 quality-adjusted life-years (QALYs) with an incremental cost of $11 700.87, resulting in an ICER value of $17 988.97 per QALY gained. Digital-powered software could be an optimal strategy in 99% of iterations against willingness-to-pay thresholds of $32 255/QALY gained. The ICER was most sensitive to the annual cost of a digital monitoring solution for hypothyroidism. CONCLUSION: The incorporation of the digital monitoring solution has demonstrated positive cost-effectiveness in hypothyroidism management when compared to the standard care. The cost of the digital monitoring solution and its sensitivity are key factors in determining cost-effectiveness. Striking a balance among the cost of digital monitoring support, the precision of hormonal level monitoring, and its effectiveness for the specific group of hypothyroid patients in real-world clinical practice is essential.
引用
- Kim JH, Shin J, Kim MS, et al. Cost-effectiveness Analysis Comparing Conventional and Digital Software Supported Management for Hypothyroidism. J Clin Endocrinol Metab. 2025. PMID: 39446462. doi:10.1210/clinem/dgae751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。